General Information of Drug Combination (ID: DCCH7JN)

Drug Combination Name
Terameprocol FORMESTANE
Indication
Disease Entry Status REF
Large cell lung carcinoma Investigative [1]
Component Drugs Terameprocol   DMC3P45 FORMESTANE   DMWIDJK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: NCI-H460
Zero Interaction Potency (ZIP) Score: 1.84
Bliss Independence Score: 2.79
Loewe Additivity Score: 0.7
LHighest Single Agent (HSA) Score: 0.09

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of FORMESTANE
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Withdrawn from market [3]
FORMESTANE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
FORMESTANE Interacts with 5 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Adenylate kinase isoenzyme 1 (AK1) OT614AR3 KAD1_HUMAN Increases ADR [5]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Activity [6]
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) OT6EBDHM DHB1_HUMAN Decreases Activity [7]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [8]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Expression [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCI7XJI HL-60(TB) Investigative [9]
Astrocytoma DCDK4FE U251 Investigative [9]
Childhood T acute lymphoblastic leukemia DCQ06SU CCRF-CEM Investigative [9]
Clear cell renal cell carcinoma DCMXN65 786-0 Investigative [9]
Clear cell renal cell carcinoma DC4CMM2 CAKI-1 Investigative [9]
Glioma DCBT0OR SF-295 Investigative [9]
Plasma cell myeloma DCI323K RPMI-8226 Investigative [9]
Colon adenocarcinoma DCZW91A COLO 205 Investigative [10]
Adenocarcinoma DCQ5KCF OVCAR3 Investigative [1]
Adenocarcinoma DCTGLTL HCT116 Investigative [1]
Adenocarcinoma DCQEH2M SW-620 Investigative [1]
Adenocarcinoma DC23I9R HT29 Investigative [1]
Amelanotic melanoma DCU7YSO M14 Investigative [1]
Cutaneous melanoma DCQ01SW SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCOY3T3 NCI\\/ADR-RES Investigative [1]
Malignant melanoma DCUOXAK UACC62 Investigative [1]
Minimally invasive lung adenocarcinoma DCP5MTL NCI-H322M Investigative [1]
Prostate carcinoma DCCJYXM PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. Toxicol In Vitro. 2000 Jun;14(3):227-34.
7 Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol. 2005 Apr;94(5):461-7.
8 Androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays. Toxicol Lett. 2018 Aug;292:39-45. doi: 10.1016/j.toxlet.2018.04.026. Epub 2018 Apr 24.
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
10 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.